Search

Displaying results 651 - 660 of 3917 in total
  1. Drug

    Pariglasgene brecaparvovec

    go.drugbank.com/drugs/DB16801
    Approved

    continued approval potentially contingent on confirmatory trials. … [L64050] The FDA granted pariglasgene brecaparvovec-opnr accelerated approval on August 19, 2026, making it the first approved treatment for glycogen storage disease type Ia.

  2. Drug

    Fish oil

    go.drugbank.com/drugs/DB13961
    ApprovedInvestigationalNutraceutical

    Such fish oils are available in both non-prescription and prescription-only varieties at different concentrations. … For many individuals, taking non-prescription fish oils as part of their multivitamin regimen is an effective way to supplement their diets with the healthy fatty acids.

  3. Drug

    Quercus alba pollen

    go.drugbank.com/drugs/DB10376
    Approved

    Quercus alba pollen, or oak white pollen, is a non-standardized allergen extract used for the diagnosis and treatment of allergic disease to grass pollen.

    Categories: Non-Standardized Pollen Allergenic Extract
  4. Drug

    Linvoseltamab

    go.drugbank.com/drugs/DB17447
    ApprovedInvestigational

    Linvoseltamab (INN), marketed as Lynozyfic™, is a bispecific human IgG4 monoclonal antibody developed by Regeneron that promotes the interaction of B-cell maturation antigen (BCMA) on multiple myeloma

  5. Drug

    Plant-based virus-like particles, recombinant, adjuvanted COVID-19 vaccine

    go.drugbank.com/drugs/DB16757
    Approved

    [A245824] In addition, VLPs contain no viral material and are therefore inherently non-infectious, making them potentially safer alternatives to traditional vaccines.[A245824]

  6. Drug

    Imipramine

    go.drugbank.com/drugs/DB00458
    ApprovedInvestigational

    They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, imipramine does not affect mood or arousal, but may cause sedation. … In depressed individuals, imipramine exerts a positive effect on mood. TCAs are potent inhibitors of serotonin and norepinephrine reuptake.

    Categories: Non-Selective Monoamine Reuptake Inhibitors
  7. Drug

    Palopegteriparatide

    go.drugbank.com/drugs/DB18676
    ApprovedInvestigational

    [L51134] Palopegteriparatide was first approved by the EMA on November 17, 2023, for the treatment of hyperparathyroidism.[L51134] On August 8, 2024, palopegteriparatide was also approved by the FDA.

  8. Drug

    Vernakalant

    go.drugbank.com/drugs/DB06217
    ApprovedInvestigational

    Vernakalant was developed by Cardiome Pharma as as an antiarrhythmic drug intended for rapid conversion of atrial fibrillation to sinus rhythm. It acts as an atypical class III antiarrhythmic drug that potentiates its effect in higher he...

  9. Drug

    Vinblastine

    go.drugbank.com/drugs/DB00570
    ApprovedInvestigational

    Antitumor alkaloid isolated from Vinca rosea. (Merck, 11th ed.)

  10. Drug

    Linagliptin

    go.drugbank.com/drugs/DB08882
    ApprovedInvestigational

    Linagliptin was approved by the FDA on May 2, 2011[L9557]. … Linagliptin differs from other DPP-4 inhibitors in that it has a non-linear pharmacokinetic profile, is not primarily eliminated by the renal system, and obeys concentration dependant protein binding[A37050